28271030|t|High-fidelity Glucagon-CreER mouse line generated by CRISPR-Cas9 assisted gene targeting
28271030|a|α-cells are the second most prominent cell type in pancreatic islets and are responsible for producing glucagon to increase plasma glucose levels in times of fasting. α-cell dysfunction and inappropriate glucagon secretion occur in both type 1 and type 2 diabetes. Thus, there is growing interest in studying both normal function and pathophysiology of α-cells. However, tools to target gene ablation or activation specifically of α-cells have been limited, compared to those available for β-cells. Previous Glucagon-Cre and Glucagon-CreER transgenic mouse lines have suffered from transgene silencing, and the only available Glucagon-CreER "knock-in" mouse line results in glucagon haploinsufficiency, which can confound the interpretation of gene deletion analyses. Therefore, we sought to develop a Glucagon-CreER(T2) mouse line that would maintain normal glucagon expression and would be less susceptible to transgene silencing. We utilized CRISPR-Cas9 technology to insert an IRES-CreER(T2) sequence into the 3' UTR of the Glucagon (Gcg) locus in mouse embryonic stem cells (ESCs). Targeted ESC clones were then injected into mouse blastocysts to obtain Gcg-CreER(T2) mice. Recombination efficiency in GCG (+) pancreatic α-cells and glucagon-like peptide 1 positive (GLP1(+)) enteroendocrine L-cells was measured in Gcg-CreER(T2); Rosa26-LSL-YFP mice injected with tamoxifen during fetal development and adulthood. Tamoxifen injection of Gcg-CreER(T2); Rosa26-LSL-YFP mice induced high recombination efficiency of the Rosa26-LSL-YFP locus in perinatal and adult α-cells (88% and 95%, respectively), as well as in first-wave fetal α-cells (36%) and adult enteroendocrine L-cells (33%). Mice homozygous for the Gcg-CreER(T2) allele were phenotypically normal. We successfully derived a Gcg-CreER(T2) mouse line that expresses CreER(T2) in pancreatic α-cells and enteroendocrine L-cells without disrupting preproglucagon gene expression. These mice will be a useful tool for performing temporally controlled genetic manipulation specifically in these cell types.
28271030	14	39	Glucagon-CreER mouse line	T025	C1513528
28271030	53	64	CRISPR-Cas9	T063	C0814038
28271030	74	88	gene targeting	T063	C0242613
28271030	89	96	α-cells	T025	C0030280
28271030	127	136	cell type	T170	C0449475
28271030	140	157	pancreatic islets	T023	C0022131
28271030	192	200	glucagon	T116,T121,T125	C0017687
28271030	213	234	plasma glucose levels	T034	C0455280
28271030	247	254	fasting	T033	C0015663
28271030	256	262	α-cell	T025	C0030280
28271030	263	274	dysfunction	T077	C3887504
28271030	293	301	glucagon	T116,T121,T125	C0017687
28271030	302	311	secretion	T038	C0036536
28271030	326	332	type 1	T047	C0011854
28271030	337	352	type 2 diabetes	T047	C0011860
28271030	423	438	pathophysiology	T169	C0031847
28271030	442	449	α-cells	T025	C0030280
28271030	476	489	gene ablation	T063	C1513384
28271030	493	503	activation	T045	C0017255
28271030	520	527	α-cells	T025	C0030280
28271030	579	586	β-cells	T025	C0030281
28271030	597	609	Glucagon-Cre	T025	C1513528
28271030	614	651	Glucagon-CreER transgenic mouse lines	T025	C1513528
28271030	671	680	transgene	T028	C0282641
28271030	681	690	silencing	T045	C0598496
28271030	715	751	Glucagon-CreER "knock-in" mouse line	T025	C1513528
28271030	763	771	glucagon	T116,T121,T125	C0017687
28271030	772	790	haploinsufficiency	T049	C2936267
28271030	833	855	gene deletion analyses	T059	C1294202
28271030	891	920	Glucagon-CreER(T2) mouse line	T025	C1513528
28271030	948	956	glucagon	T028	C1333664
28271030	957	967	expression	T045	C1171362
28271030	1001	1010	transgene	T028	C0282641
28271030	1011	1020	silencing	T045	C0598496
28271030	1034	1056	CRISPR-Cas9 technology	T063	C0814038
28271030	1070	1093	IRES-CreER(T2) sequence	T086	C1512886
28271030	1103	1109	3' UTR	T086,T123	C0600600
28271030	1117	1125	Glucagon	T028	C1333664
28271030	1127	1130	Gcg	T028	C1333664
28271030	1132	1137	locus	T028	C0678933
28271030	1141	1167	mouse embryonic stem cells	T025	C4042879
28271030	1169	1173	ESCs	T025	C4042879
28271030	1185	1188	ESC	T025	C4042879
28271030	1189	1195	clones	T025	C0009013
28271030	1220	1225	mouse	T015	C0025929
28271030	1226	1237	blastocysts	T018	C1281743
28271030	1248	1266	Gcg-CreER(T2) mice	T015	C0025936
28271030	1268	1281	Recombination	T045	C0034865
28271030	1296	1299	GCG	T116,T121,T125	C0017687
28271030	1304	1322	pancreatic α-cells	T025	C0030280
28271030	1327	1359	glucagon-like peptide 1 positive	T116	C0061355
28271030	1361	1368	GLP1(+)	T116	C0061355
28271030	1370	1393	enteroendocrine L-cells	T025	C2333553
28271030	1410	1423	Gcg-CreER(T2)	T015	C0025936
28271030	1425	1444	Rosa26-LSL-YFP mice	T015	C0025936
28271030	1445	1453	injected	T061	C0021485
28271030	1459	1468	tamoxifen	T109,T121	C0039286
28271030	1476	1493	fetal development	T039	C0015928
28271030	1498	1507	adulthood	T079	C0700597
28271030	1509	1518	Tamoxifen	T109,T121	C0039286
28271030	1519	1528	injection	T061	C0021485
28271030	1532	1545	Gcg-CreER(T2)	T015	C0025936
28271030	1547	1566	Rosa26-LSL-YFP mice	T015	C0025936
28271030	1580	1593	recombination	T045	C0034865
28271030	1612	1632	Rosa26-LSL-YFP locus	T028	C0678933
28271030	1636	1645	perinatal	T079	C0178795
28271030	1650	1655	adult	T100	C0001675
28271030	1656	1663	α-cells	T025	C0030280
28271030	1724	1731	α-cells	T025	C0030280
28271030	1742	1747	adult	T100	C0001675
28271030	1748	1771	enteroendocrine L-cells	T025	C2333553
28271030	1779	1783	Mice	T015	C0025929
28271030	1784	1794	homozygous	T032	C0019904
28271030	1803	1816	Gcg-CreER(T2)	T028	C0017337
28271030	1817	1823	allele	T028	C0002085
28271030	1878	1902	Gcg-CreER(T2) mouse line	T025	C1513528
28271030	1908	1917	expresses	T045	C0017262
28271030	1918	1927	CreER(T2)	T028	C0017337
28271030	1931	1949	pancreatic α-cells	T025	C0030280
28271030	1954	1977	enteroendocrine L-cells	T025	C2333553
28271030	1997	2011	preproglucagon	T028	C1333664
28271030	2012	2027	gene expression	T045	C0017262
28271030	2035	2039	mice	T015	C0025929
28271030	2099	2119	genetic manipulation	T063	C0178659
28271030	2142	2152	cell types	T170	C0449475